OncoMatch/Clinical Trials/NCT07397832
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Is NCT07397832 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Chidamide and Rituximab for diffuse large b-cell lymphoma (dlbcl).
Treatment: Chidamide · Rituximab · Polatuzumab Vedotin · Chidamide Maintenance — A Single-Arm, Open-Label, Multicenter Phase II Trial of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin) in Treating Elderly Patients with Previously Untreated Double-Positive Diffuse Large B-Cell Lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive expression
CD20 positivity
Required: MYC positive expression
concurrent positive expression of C-MYC
Required: BCL2 positive expression
concurrent positive expression of Bcl-2
Performance status
ECOG 2–4(Completely disabled)
Prior therapy
Cannot have received: Chidamide (Chidamide)
Prior treatment with Chidamide
Cannot have received: R-CHOP (R-CHOP)
Prior treatment with ... R-CHOP
Cannot have received: anthracycline
prior anthracycline therapy
Lab requirements
Blood counts
hb ≥90 g/l, anc ≥1.5 × 10⁹/l, plt ≥90 × 10⁹/l
Kidney function
cr ≤1.5 ×uln
Liver function
tbil ≤1.5 × uln; alt and ast ≤2.5 × uln (for patients with liver involvement: ≤5 × uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify